Engaging Innate Immunity in HIV-1 Cure Strategies

Scientists discuss novel latency-reversing agents targeting DCs as well as DC-based strategies to enhance the clearance of infected cells by CD8+ T cells and strategies to improve the killing activity of natural killer cells.
[Nature Reviews Immunology]
[zotpress userid=” items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

CCR5 Antagonist Reduces HIV-Induced Amyloidogenesis, Tau Pathology, Neurodegeneration, and Blood-Brain Barrier Alterations in HIV-Infected Hu-PBL-NSG Mice

Investigators determined whether HIV-1 infection caused Alzheimer’s Disease-like pathologies in an HIV/AIDS humanized mouse model, and whether the CCR5 antagonist maraviroc altered HIV-induced pathologies.
[Molecular Neurodegeneration]
[zotpress userid=” items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Pfizer Antiviral Slashes COVID-19 Hospitalizations

Opening a new chapter in the treatment of COVID-19—one borrowed from successfully tackling the AIDS virus—the drug behemoth Pfizer reported upbeat results for a 5-day pill regimen to treat early infections with SARS-CoV-2.
[ScienceInsider]
[zotpress userid=” items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Bone Marrow Mesenchymal Stem Cell-Derived Exosomal miR-34c-5p Ameliorates Renal Interstitial Fibrosis by Inhibiting the Core Fucosylation of Multiple Proteins

Scientists revealed that MSC-derived exosomes resided specifically in the injured kidney and delivered miRNA-34c-5p to reduce cellular activation and renal interstitial fibrosis by inhibiting core fucosylation.
[Molecular Therapy]
[zotpress userid=’7992332′ items=’DDDDDDDD’ style=’apa’ cite=’yes’]
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection

Enochian BioSciences, Inc. announced the completion of a Pre-Investigational New Drug process for ENOB-HB-01, a novel approach to potentially eliminate HBV-infected liver cells with an innovative “Hijack RNA” strategy that co-opts the virus’ machinery to induce the death of infected cells rather than reproducing and causing more infection and liver disease.
[Enochian BioSciences, Inc.]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Pulmonary Histoplasmosis

Scientists review clinical manifestations, radiological findings and treatment options according to the clinical form, as well as different diagnosis tools and new laboratory tests that have been recently developed and validated and are becoming widely available.
[Mycopathologia]
[zotpress userid=” items=’9EN8B2VB’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Deafness-in-a-Dish: Modeling Hereditary Deafness with Inner Ear Organoids

Investigators discuss the advantages and limitations of conventional models of the human auditory system, describe the generation and characteristics of PSC-derived inner ear organoids, and discuss several strategies and recent attempts to model hereditary deafness in vitro.
[Human Genetics]
[zotpress userid=” items=’JXMQSTSL’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Antiviral Response Induced by TLR7/TLR8 Activation Inhibits HIV-1 Infection in Cord Blood Macrophages

Despite the phenotypic and transcriptional similarities between cord blood and adult macrophages, cord blood cells were prone to viral replication when infected with HIV-1.
[Journal of Infectious Diseases]
[zotpress userid=’6445218′ items=’9JDH39RK’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

CytoDyn’s Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase II from Phase Ib

CytoDyn, Inc., a biotechnology company developing leronlimab, a CCR5 antagonist, announced its clinical trial with leronlimab in combination with carboplatin for the treatment of metastatic TNBC has advanced from Phase Ib to a Phase II trial.
[CytoDyn, Inc.]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

HIV-1 and Human Genetic Variation

HIV host genomic research, which aims to understand how human genetic variation affects our response to HIV infection, has progressed from early candidate gene studies to recent multi-omic efforts, benefiting from spectacular advances in sequencing technology and data science.
[Nature Reviews Genetics]
[zotpress userid=” items=’86RF4BG2′ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Vpr Counteracts the Restriction of LAPTM5 to Promote HIV-1 Infection in Macrophages

Investigators reported that Vpr counteracts lysosomal-associated transmembrane protein 5 (LAPTM5), a potent inhibitor of HIV-1 particle infectivity, to enhance HIV-1 infection in macrophages.
[Nature Communications]
[zotpress userid=’6445218′ items=’ZD42PEJZ’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share
Share